[Form 4] Ocuphire Pharma, Inc. Common Stock Insider Trading Activity

Rhea-AI Filing Summary

Opus Genetics, Inc. director Sean Ainsworth reported an open-market purchase of 86,956 shares of the company's common stock on 08/25/2025 at a price of $1.15 per share, increasing his beneficial ownership to 254,818 shares. The Form 4 was signed via power of attorney on 08/27/2025. The filing shows no reported derivative transactions.

Positive

• Director purchase reported: Sean Ainsworth acquired 86,956 common shares, increasing his stake to 254,818 shares.
• Transparent disclosure: The transaction was reported on Form 4 and signed by power of attorney on 08/27/2025.

Negative

• None.

Insights

Securities Analyst

TL;DR: A director increased direct ownership by 86,956 shares at $1.15, modest insider purchase that raises alignment with shareholders.

The reported transaction is a straightforward non-derivative acquisition: 86,956 common shares were purchased on 08/25/2025 for $1.15 each, bringing the reporting person’s total to 254,818 shares. The Form 4 contains no derivative positions or dispositions. The filing was executed by power of attorney and properly reported within a standard timeframe.

Corporate Governance Expert

TL;DR: Director purchase disclosed timely; strengthens insider alignment but provides limited material insight alone.

The disclosure documents an insider purchase by a director, which generally signals increased alignment between management and shareholders. The form does not disclose any option exercises or derivative activity. No amendments or additional reporting persons are indicated. As a single Form 4 with a routine purchase, it appears to be a standard Section 16 disclosure without other governance events.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ainsworth Sean

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NC 27713

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		A		86,956	A	$1.15	254,818	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Amy Rabourn, by Power of Attorney	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did the reporting person disclose on the Form 4?

The Form 4 discloses a purchase of 86,956 shares of common stock on 08/25/2025 at $1.15 per share.

How many shares does Sean Ainsworth beneficially own after the transaction?

The filing reports beneficial ownership of 254,818 shares following the purchase.

Were any derivative securities reported in this Form 4?

No. The filing contains no reported derivative securities; only a non-derivative common stock acquisition is shown.

When was the Form 4 signed and filed?

The signature on the Form 4 was executed by power of attorney on 08/27/2025.

Which company is the issuer named in the Form 4?

The issuer named in the filing is Opus Genetics, Inc. (as listed on the Form 4).